





# Gynecologic Oncology Biannual Meeting Fall 2021 Meeting



Cancer care. Patients first.  
The best care. Everywhere.

**Welcome**

**MOQC**  
MICHIGAN ONCOLOGY  
QUALITY CONSORTIUM

moqc.org



# Connecting



# MOQC Testimonials

## Testimonial Survey Link

[https://umich.qualtrics.com/jfe/form/SV\\_4VLyypOsOwee806](https://umich.qualtrics.com/jfe/form/SV_4VLyypOsOwee806)



## Continuing Education Credits

- **MiCME: 3 AMA PRA Category 1 Credit(s)<sup>TM</sup>**



# Agenda


	Topic	Facilitator(s)
9:05 a.m.	Patient & Caregiver Update	Amanda Itliong, MA
9:20 a.m.	Ovarian Cancer Resources Update	Vanessa Aron, BA
9:40 a.m.	Data & Updates	Shitanshu Uppal, MD
10:10 a.m.	MSQC Data	Shitanshu Uppal, MD
10:50 a.m.	Break	
11:00 a.m.	Literature Review	Shitanshu Uppal, MD



# POQC Update

Amanda Itliong





# Ovarian Cancer Resources

Vanessa Aron



# Resources

<https://moqc.org>



About Initiatives News Events **Resources** 

## Abstraction

Round 1 Abstraction

## CLINICAL

Chemotherapy-Induced  
Nausea and Vomiting (CINV)  
– Antiemetics  
Oral Oncolytics  
Tobacco Cessation Program

## GRANT-FUNDED

Patient-Reported  
Outcomes in Oncology  
(PROMOnc)

## GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series  
Ovarian Cancer Resources  
Past Meeting Library  
Standardized Op Note  
VTE Khorana Calculator  
VTE Prophylaxis Calculator

## INTERDISCIPLINARY PARTNERSHIPS

Hospice  
Palliative Radiation Therapy  
Pathway  
Pharmacists Optimizing  
Oncology Care Excellence in  
Michigan (POEM)  
Primary Care Oncology Model  
(PCOM)

# Resources

GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series

Ovarian Cancer Resources

Past Meeting Library

Standardized Op Note

VTE Khorana Calculator

VTE Prophylaxis Calculator

<https://mogc.org>

Home

GYOEDU Lectures

External Lectures

Study Summaries

Surgical Videos

Lecture Schedule

Educational Tweets

Signup

Search



## Gynecologic Oncology Educational Series

Support GYOEDU.org

 [Become a patron](#)

### Who are we?

GYOEDU was founded in 2020. We aim to build an inclusive educational community for GYN Oncology based on a model of high-quality, easily-accessible, peer-reviewed content free from commercial bias. We focus on goals and objectives for GYN Oncology fellows and those interested in pursuing fellowship. Our shared vision is knowing that strength comes from ensuring the success of those around us. Just as the highest quality health care organizations implement reliable and reproducible systems in order to elevate patient care, we aim to provide standardized curricula for teaching GYN Oncology throughout the world.

**GYOEDU Team**

# Resources

## GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series

Ovarian Cancer Resources

Past Meeting Library

Standardized Op Note

VTE Khorana Calculator

VTE Prophylaxis Calculator

## Standardized Operative Note

### Checklist for Ovarian Cancer Operative Note Dictation



[CLICK HERE for an online operative note generator](#)

Please make sure to include the following data elements in your operative note.

- **Debulking Status** – Primary vs. Interval Debulking
- **Staging Information** – If available based on imaging (for example, at least stage IIIc for a patient with a biopsy-proven lesion of the omentum) [Link to ovarian cancer staging](#)
- **Surgery Type** – Open/Robotic/Laparoscopic
- **Residual Disease Status** – Please specify if:
  - No residual disease (R0 or no visible disease)
  - Optimally debulked (1-5 mm largest visible disease)
  - Optimally debulked (6-10 mm visible disease)
  - Sub-optimally debulked (>10 mm disease residual)
    - For suboptimally debulked patients, specify the size and location of residual disease
- **Surgical Complexity Scoring** – Use the calculator below to get the score  
(Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1-e7.)

# Resources

## GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series

Ovarian Cancer Resources

Past Meeting Library

Standardized Op Note

VTE Khorana Calculator

VTE Prophylaxis Calculator



## MOQC VTE Calculator

Age:

≤40 41-60 61-74 ≥75

Type of Surgery:

Minimally Invasive Open Vaginal/Vulvar

Operation Time:

<45 mins 45 to 180 mins >180 mins

No 0 Yes +1

No 0 Yes +2

No 0 Yes +1

No 0 Yes +1

No 0 Yes +1

No 0 Yes +1

No 0 Yes +1

## Khorana Risk Score for Venous Thromboembolism in Cancer Patients ☆

Predicts risk of VTE for cancer patients depending on type of cancer and other factors.

### INSTRUCTIONS

Use in general cancer patients (i.e., solid tumors and lymphomas). Do not use in patients with brain tumors or myelomas.

When to Use ▼

Pearls/Pitfalls ▼

Why Use ▼

Cancer type

Stomach	+2
Pancreas	+2
Lung	+1
Lymphoma	+1

**Result:**

### About the Creator



Dr. Alok Khorana ✓

### Also from MDCalc...

#### Related Calcs

- POMPE-C Tool
- Hestia Criteria
- PERC Rule

# Resources

Home News Events Resources

## GYNECOLOGIC ONCOLOGY

- Gyn Onc Educational Series
- Ovarian Cancer Resources**
- Past Meeting Library
- Standardized Op Note
- VTE Khorana Calculator
- VTE Prophylaxis Calculator

## MOQC


- Becoming a MOQC Practice
- VBR: Value-Based Reimbursement
- Past Meeting Library
- Printed Resources

[www.ovariancancerpodcast.com](http://www.ovariancancerpodcast.com)

### Educational Materials


#### Ovarian Cancer Checklists:

##### For Patients




This document will serve as a tool to help you suggest your ovarian cancer care with your health care team. The document contains information about ovarian cancer, its treatment, and how you can be involved in your care. It also includes a checklist of questions to ask your doctor.

##### For Physicians



CONSIDERING A GYNECOLOGIC ONCOLOGY REFERRAL? Please consider reviewing this document before or after your referral. It includes a checklist of questions to ask your doctor.


#### Educational Videos:



MOQC Ovarian Cancer: Side Effects of Chemotherapy

### Ovarian Cancer Education Podcasts


#### Featured podcast:



Ovarian Cancer Education Podcast  
**Chemotherapy, Part 1**

9/17/2021 • 27 min • Listen later

View terms



Ovarian Cancer Education Podcast  
**Chemotherapy, Part 2**

9/17/2021 • 33 min • Listen later

View terms

#### Additional podcasts:

- Season 1, Ep. 3: Chemotherapy, Part 2
- Season 1, Ep. 3: Chemotherapy, Part 1
- Season 1, Ep. 2: Treatment Options
- Season 1, Ep. 1: New Diagnosis

#### Newsletter:

If you are interested in hearing about podcast episodes as they are



[www.ovariancancerpodcast.com](http://www.ovariancancerpodcast.com)

## Ovarian Cancer Education Podcasts

### Featured podcast:

	Ovarian Cancer Education Podcast <b>Chemotherapy, Part 1</b>	<a href="#">Share</a> <a href="#">+ Follow</a> <a href="#">Acast</a>
	9/17/2021 • 27 min • <a href="#">Listen later</a>	<a href="#">View terms</a>
	Ovarian Cancer Education Podcast <b>Chemotherapy, Part 2</b>	<a href="#">Share</a> <a href="#">+ Follow</a> <a href="#">Acast</a>
	9/17/2021 • 33 min • <a href="#">Listen later</a>	<a href="#">View terms</a>

### Additional podcasts:

-  Season 1, Ep. 3: Chemotherapy, Part 2
-  Season 1, Ep. 3: Chemotherapy, Part 1
-  Season 1, Ep. 2: Treatment Options
-  Season 1, Ep. 1: New Diagnosis



[www.ovariancancerpodcast.com](http://www.ovariancancerpodcast.com)

## Ovarian Cancer Education Podcasts

### Featured podcast:



Ovarian Cancer Education Podcast  
**Chemotherapy, Part 1**

9/17/2021 • 27 min • [Listen later](#)

[Share](#) [+ Follow](#) [Acast](#)

[View terms](#)







Ovarian Cancer Education Podcast  
**Chemotherapy, Part 2**

9/17/2021 • 33 min • [Listen later](#)

[Share](#) [+ Follow](#) [Acast](#)

[View terms](#)


### Additional podcasts:

-  Season 1, Ep. 3: Chemotherapy, Part 2
-  Season 1, Ep. 3: Chemotherapy, Part 1
-  Season 1, Ep. 2: Treatment Options
-  Season 1, Ep. 1: New Diagnosis

- Side Effects of Chemotherapy
- Ports
- What to Expect for Debulking Surgery
- Regimen vs. Cycle vs. Course

[www.ovariancancerpodcast.com](http://www.ovariancancerpodcast.com)

#### Educational Videos:





## Resources

### GYNECOLOGIC ONCOLOGY

Gyn Onc Educational Series

Ovarian Cancer Resources

Past Meeting Library

Standardized Op Note

VTE Khorana Calculator

VTE Prophylaxis Calculator

[www.ovariancancerpodcast.com](http://www.ovariancancerpodcast.com)

### Newsletter:


If you are interested in hearing about podcast episodes as they are published, or about other ovarian cancer related resources, please sign up for our newsletter:

Ovarian Cancer Education Newsletter

# Data & Updates

Shitanshu Uppal





## Measure Selection Strategy



# MOQC Value Based Reimbursement (VBR)


## ELIGIBILITY

Region meets target for 2 of 2 designated VBR measures

+

One physician per practice attends both biannual meetings

## PAYMENT



Retrospective care (abstraction)



Prospective payment





# MOQC Value Based Reimbursement (VBR)


More information about VBR in meeting materials

<https://bit.ly/3Gn7uqr>





### Collaborative Quality Initiatives Fact Sheet Value-Based Reimbursement 2022



#### Michigan Oncology Quality Consortium

The Value Partnerships program at Blue Cross develops and maintains quality programs to align practitioner reimbursement with quality of care standards, improve health outcomes and control health care costs. Practitioner reimbursement earned through these quality programs is called value-based reimbursement (VBR). The VBR Fee Schedule sets fees at greater than 100% of the Standard Fee Schedule. VBR opportunities include PGIP practitioners who participate in the Michigan Oncology Quality Consortium (MOQC), and that meet specific eligibility criteria. The coordinating center clinical leadership, jointly with Blue Cross, set quality and performance metrics for its VBR. Each CQI uses unique measures and population-based scoring to receive Blue Cross VBR.

**Population-Based Scoring Methodology**  
The CQI coordinating center (not the physician organization) determines which practitioners have met the appropriate performance targets and notifies Blue Cross. Each physician organization will notify practitioners who will receive CQI VBR, just as the POs do for other forms of specialist VBR. MOQC practitioners must achieve target on all measures listed for their respective disciplines to be eligible to receive 103% CQI VBR. MOQC does not currently have an option to receive a maximum CQI VBR of 105% of the standard fee schedule.

To be eligible for MOQC VBR, practitioners must meet the following scoring criteria:

(See Table 1 below) Medical oncologists participating in MOQC measure performance at a regional level where oncology practices are grouped into five geographic regions. Each geographic region must collectively achieve the target on 3 of 4 measures to be eligible to earn 103% CQI VBR.

(See Table 2 below) Gynecological oncologists participating in MOQC measure performance at the collaborative level. All of the gynecologic oncology practices must meet the targets for 2 of 2 measures to be eligible to earn 103% CQI VBR.

Participants can only receive one CQI VBR even if they are participating in more than one CQI. CQI VBR is not additive if the practitioner is contributing data to multiple CQIs. However, if a practitioner is eligible for rewards through multiple CQIs, the practitioner will be awarded the highest level of CQI VBR.

**VBR Measures**

**Table 1. Medical oncology measures**

Measure (ASCO QOPI® based measures)	Measurement Period	Target
NK1 receptor antagonist or olanzapine prescribed or administered with Cycle 1 high emetic risk chemotherapy (Lower Score Better)	03/01/21 - 02/28/2022	25%
NK1 receptor antagonist or olanzapine administered for low or moderate emetic risk Cycle 1 chemotherapy (lower score - better)	03/01/21 - 02/28/2022	14%

## MOQC's VBR Measures & Targets


TO BE PAID TO ELIGIBLE PHYSICIANS Performance Year 2021 VBR Payment 2022	
MOQC VBR Measures	Target
Days between Cyto reduction and 1 <sup>st</sup> Day of Chemotherapy	≤28 days
Operative report with documentation of residual disease	70%



## Core and Symptom Measures

- Oral chemotherapy monitored and addressed on visit/contact following start of therapy
- Signed patient consent for chemotherapy
- Tobacco cessation counseling administered or patient referred in past year


Oral chemotherapy monitored on visit/contact following start of therapy: medication adherence assessed  
N = 9



**QOPI Measure CORE 13oc6a - Practice and Comparative Groups  
R1 2021**

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.


## Signed patient consent for chemotherapy N = 177



### QOPI Measure CORE14 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.


Tobacco cessation counseling administered or patient referred in past year  
N = 29



**QOPI Measure CORE22bb - Practice and Comparative Groups  
R1 2021**

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

# Infertility risks discussed prior to chemotherapy with patients of reproductive age N = 5




## QOPI Measure SMT33 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

## End-of-Life Measures

- Pain addressed appropriately
- Dyspnea addressed appropriately
- Hospice enrollment within 3 days of death (Lower score better)
- Chemotherapy administered within the last two weeks of life


Pain addressed appropriately  
N = 41



### QOPI Measure EOL38 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

# Dyspnea addressed appropriately N = 32




## QOPI Measure EOL41 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

## Hospice enrollment within 3 days of death (Lower score better)


N = 20



### QOPI Measure EOL44 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

# Chemotherapy administered within the last two weeks of life N = 41




## QOPI Measure EOL48 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

## Gynecologic Oncology Measures

- Patients with ovarian cancer referred to genetic testing/counselling
- Platinum and taxane administered within 28 days following cytoreduction (or staging surgery) to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer
- Days between cytoreduction and 1<sup>st</sup> day of chemotherapy — **VBR Measure**
- Operative note with documentation of residual disease — **VBR Measure**
  - Within 48 hours
  - Beyond 48 hours


Patients with ovarian cancer referred to genetic testing/counselling  
N = 109



**QOPI Measure GynOnc #2 - Practice and Comparative Groups  
R1 2021**

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

Platinum and taxane administered within 28 days following cytoreduction (or staging surgery) to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer  
N = 91




### QOPI Measure GYNONC94 - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

# Days between Cytoresduction and 1st Day of Chemotherapy


N = 62



Each bar = 1 Patient

Operative report with documentation of residual disease (Optimal/Suboptimal)  
N = 122


Within 48 hours



**QOPI Measure GYNONC90g - Practice and Comparative Groups  
R1 2021**

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.


## Operative report with documentation of residual disease



**QOPI CORE Measure GYNONC90g**

# Operative report with documentation of residual disease (Optimal/Suboptimal) N = 142


Beyond 48 hours



## QOPI Measure GYNONC90g - Practice and Comparative Groups R1 2021

Note: Practices with no eligible cases in the denominator and/or missing data are not shown.

## Operative report with documentation of residual disease



**QOPI CORE Measure GYNONC90g**

## New Target

TO BE PAID TO ELIGIBLE PHYSICIANS Performance Year 2022 VBR Payment 2023	
MOQC VBR Measures	Target
Days between Cytoreduction and 1 <sup>st</sup> Day of Chemotherapy	≤28 days

??%



## Discussion



# MSQC Data


Shitanshu Uppal




## MSQC Data

- Cases abstracted by MSQC if surgeon is a Gynecologic Oncologist participating with MOQC
  - 235 Hysterectomies – Benign Final pathology (including CAH)
  - 399 Hysterectomies – Cancer final pathology


# Emergency Room Utilization




# Readmission Rates




# Reoperation Rates




# Serious Complications




# Surgical Site Infections



# Urinary Tract Infection



# Venous Thromboembolism





## Discussion





**Break**



# Journal Review

Shitanshu Uppal



## Closing Items

- Testimonial Survey Link
- Upcoming Events: <https://moqc.org/events/>  
**MOQC Gynecologic Oncology Biannual Meeting**  
Saturday, April 23, 2022  
Location: TBD
- Claim your CME/CEU credit for this meeting



# Cancer Genomics Webinar

**Thursday, October 14, 2021**  
**12:00 noon - 1:00 p.m. EST**

**“Ovarian Cancer and Genetic Services in Michigan:  
A Surveillance Report, 2008-2018”**

Jessica Fritzler, MPH  
Epidemiologist, MDHHS Cancer Genomics Program

**“Implementation of Strategies to Increase Genetic Counseling Referral Rates for Ovarian Cancer Patients”**

Kara Milliron, MS, CGC  
Genetic Counselor, Breast and Ovarian Cancer Risk Evaluation Clinic,  
Michigan Medicine

**How to Join on October 14**

[Join Microsoft Teams Meeting](#)

**Or call in (audio only)**

[+1 248-509-0316](#)

Phone Conference ID: 899 264 854#

## Two Continuing Education Webinars



### Genetic Risk Assessment for Hereditary Cancer Syndromes

**Release Date:** Fri, 1/15/21

**Termination Date:** Fri, 12/31/21

**Credits Available:**

**AMA PRA Category 1:** 0.75

**Participation:** 0.75

Fee waived for MOQC Members

---

In Partnership with Michigan Department of Health and Human Services

### Survivorship Programs to Support Quality of Life

**Release Date:** Tues, 3/30/21

**Termination Date:** Pending

**Credits Available:**

**AMA PRA Category 1:** Approval Pending

**Participation:** Approval Pending

**Social Work CE Credit:** 1.0

Fee waived for MOQC Members

<https://moqc.org/resources/continuing-education-opportunities/>

# Continuing Education Credit – Creating an Account

## Steps to create a MiCME Account:

1. Go to <https://ww2.highmarksce.com/micme/>
2. Click the “Create a MiCME Account” tile at the bottom of the screen
3. Under New User? click “Create a MiCME Account”
4. Enter the Profile Information questions, confirm consent, and click “Create a MiCME Account”
5. Enter your password and complete your profile.  
Your MiCME account is created and you can now claim continuing education credits



## Steps to Claim Credits and Print a Transcript

1. Once your MiCME account has been created, navigate to your Dashboard
2. Click on *Claim Credits and View Certificates*
3. Locate ‘**MOQC Gynecology Oncology Fall 2021 Meeting**’ in the *Activities Available for Credit Claiming* section
4. Under Action, click on *Claim. Add Credit.*
5. Enter the number of credits you are claiming and the “*I Attest*” button.
6. Complete the evaluation.
7. Click the *Submit* button
8. Scroll down to the *Awarded Credits* section to view or print your certificate and/or comprehensive University of Michigan CME transcript.

If you have any difficulties, email  
[moqc@moqc.org](mailto:moqc@moqc.org)  
We will assist you and resolve any issue!





**Thank You!**

